You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: October 31, 2024

~ Buy the VOSEVI (sofosbuvir; velpatasvir; voxilaprevir) Drug Profile, 2024 PDF Report in the Report Store ~

VOSEVI Drug Patent Profile


✉ Email this page to a colleague

« Back to Dashboard


Which patents cover Vosevi, and when can generic versions of Vosevi launch?

Vosevi is a drug marketed by Gilead Sciences Inc and is included in one NDA. There are eighteen patents protecting this drug.

This drug has six hundred and twenty-two patent family members in forty-nine countries.

The generic ingredient in VOSEVI is sofosbuvir; velpatasvir; voxilaprevir. There are nine drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the sofosbuvir; velpatasvir; voxilaprevir profile page.

DrugPatentWatch® Generic Entry Outlook for Vosevi

Vosevi was eligible for patent challenges on June 28, 2020.

By analyzing the patents and regulatory protections it appears that the earliest date for generic entry will be December 1, 2037. This may change due to patent challenges or generic licensing.

There have been three patent litigation cases involving the patents protecting this drug, indicating strong interest in generic launch. Recent data indicate that 63% of patent challenges are decided in favor of the generic patent challenger and that 54% of successful patent challengers promptly launch generic drugs.

Indicators of Generic Entry

< Available with Subscription >

  Sign Up

AI Research Assistant
Questions you can ask:
  • What is the 5 year forecast for VOSEVI?
  • What are the global sales for VOSEVI?
  • What is Average Wholesale Price for VOSEVI?
Drug patent expirations by year for VOSEVI
Drug Prices for VOSEVI

See drug prices for VOSEVI

DrugPatentWatch® Estimated Loss of Exclusivity (LOE) Date for VOSEVI
Generic Entry Date for VOSEVI*:
Constraining patent/regulatory exclusivity:
NDA:
Dosage:
TABLET;ORAL

*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Recent Clinical Trials for VOSEVI

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
Peking University People's HospitalPhase 4
Partners in HealthPhase 4
Gilead SciencesPhase 3

See all VOSEVI clinical trials

US Patents and Regulatory Information for VOSEVI

VOSEVI is protected by nineteen US patents.

Based on analysis by DrugPatentWatch, the earliest date for a generic version of VOSEVI is ⤷  Sign Up.

This potential generic entry date is based on patent ⤷  Sign Up.

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

Patents protecting VOSEVI

Combination formulation of three antiviral compounds
Patent Number: ⤷  Sign Up
Patent Expiration: ⤷  Sign Up

Combination formulation of two antiviral compounds
Patent Number: ⤷  Sign Up
Patent Expiration: ⤷  Sign Up

Combination formulation of three antiviral compounds
Patent Number: ⤷  Sign Up
Patent Expiration: ⤷  Sign Up

Nucleoside phosphoramidate prodrugs
Patent Number: ⤷  Sign Up
Patent Expiration: ⤷  Sign Up

Nucleoside phosphoramidate prodrugs
Patent Number: ⤷  Sign Up
Patent Expiration: ⤷  Sign Up

Antiviral compounds
Patent Number: ⤷  Sign Up
Patent Expiration: ⤷  Sign Up

Nucleoside phosphoramidate prodrugs
Patent Number: ⤷  Sign Up
Patent Expiration: ⤷  Sign Up

Nucleoside phosphoramidates
Patent Number: ⤷  Sign Up
Patent Expiration: ⤷  Sign Up

Nucleoside phosphoramidates
Patent Number: ⤷  Sign Up
Patent Expiration: ⤷  Sign Up

Nucleoside phosphoramidate prodrugs
Patent Number: ⤷  Sign Up
Patent Expiration: ⤷  Sign Up

Compositions and methods for treating hepatitis C virus
Patent Number: ⤷  Sign Up
Patent Expiration: ⤷  Sign Up

Antiviral compounds
Patent Number: ⤷  Sign Up
Patent Expiration: ⤷  Sign Up

Antiviral compounds
Patent Number: ⤷  Sign Up
Patent Expiration: ⤷  Sign Up

Nucleoside phosphoramidate prodrugs
Patent Number: ⤷  Sign Up
Patent Expiration: ⤷  Sign Up
Patented Use: TREATMENT OF ADULT PATIENTS WITH CHRONIC HCV INFECTION WHO HAVE GENOTYPE 1A OR 3 INFECTION AND HAVE PREVIOUSLY BEEN TREATED WITH AN HCV REGIMEN CONTAINING SOFOSBUVIR WITHOUT AN NS5A INHIBITOR

Nucleoside phosphoramidate prodrugs
Patent Number: ⤷  Sign Up
Patent Expiration: ⤷  Sign Up
Patented Use: TREATMENT OF ADULT PATIENTS WITH CHRONIC HCV INFECTION WHO HAVE GENOTYPE 1, 2, 3, 4, 5, OR 6 INFECTION AND HAVE PREVIOUSLY BEEN TREATED WITH AN HCV REGIMEN CONTAINING AN NS5A INHIBITOR

Nucleoside phosphoramidate prodrugs
Patent Number: ⤷  Sign Up
Patent Expiration: ⤷  Sign Up

Nucleoside phosphoramidates
Patent Number: ⤷  Sign Up
Patent Expiration: ⤷  Sign Up

Inhibitors of hepatitis C virus
Patent Number: ⤷  Sign Up
Patent Expiration: ⤷  Sign Up

Antiviral compounds
Patent Number: ⤷  Sign Up
Patent Expiration: ⤷  Sign Up

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Gilead Sciences Inc VOSEVI sofosbuvir; velpatasvir; voxilaprevir TABLET;ORAL 209195-001 Jul 18, 2017 RX Yes Yes ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
Gilead Sciences Inc VOSEVI sofosbuvir; velpatasvir; voxilaprevir TABLET;ORAL 209195-001 Jul 18, 2017 RX Yes Yes ⤷  Sign Up ⤷  Sign Up Y ⤷  Sign Up
Gilead Sciences Inc VOSEVI sofosbuvir; velpatasvir; voxilaprevir TABLET;ORAL 209195-001 Jul 18, 2017 RX Yes Yes ⤷  Sign Up ⤷  Sign Up Y ⤷  Sign Up
Gilead Sciences Inc VOSEVI sofosbuvir; velpatasvir; voxilaprevir TABLET;ORAL 209195-001 Jul 18, 2017 RX Yes Yes ⤷  Sign Up ⤷  Sign Up Y ⤷  Sign Up
Gilead Sciences Inc VOSEVI sofosbuvir; velpatasvir; voxilaprevir TABLET;ORAL 209195-001 Jul 18, 2017 RX Yes Yes ⤷  Sign Up ⤷  Sign Up Y ⤷  Sign Up
Gilead Sciences Inc VOSEVI sofosbuvir; velpatasvir; voxilaprevir TABLET;ORAL 209195-001 Jul 18, 2017 RX Yes Yes ⤷  Sign Up ⤷  Sign Up Y ⤷  Sign Up
Gilead Sciences Inc VOSEVI sofosbuvir; velpatasvir; voxilaprevir TABLET;ORAL 209195-001 Jul 18, 2017 RX Yes Yes ⤷  Sign Up ⤷  Sign Up Y ⤷  Sign Up
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

International Patents for VOSEVI

When does loss-of-exclusivity occur for VOSEVI?

Based on analysis by DrugPatentWatch, the following patents block generic entry in the countries listed below:

Argentina

Patent: 8616
Patent: FORMULACIÓN COMBINADA DE TRES COMPUESTOS ANTIVIRALES
Estimated Expiration: ⤷  Sign Up

Australia

Patent: 17273851
Patent: Combination formulation of three antiviral compounds
Estimated Expiration: ⤷  Sign Up

Brazil

Patent: 2017011025
Patent: formulação de combinação de três compostos antivirais
Estimated Expiration: ⤷  Sign Up

Canada

Patent: 25380
Patent: FORMULATION COMBINEE DE TROIS COMPOSES ANTIVIRAUX (COMBINATION FORMULATION OF THREE ANTIVIRAL COMPOUNDS)
Estimated Expiration: ⤷  Sign Up

China

Patent: 9310678
Patent: 三种抗病毒化合物的组合制剂 (Combination formulation of three antiviral compounds)
Estimated Expiration: ⤷  Sign Up

Eurasian Patent Organization

Patent: 1892376
Patent: КОМБИНИРОВАННЫЙ СОСТАВ ТРЕХ ПРОТИВОВИРУСНЫХ СОЕДИНЕНИЙ
Estimated Expiration: ⤷  Sign Up

European Patent Office

Patent: 63346
Patent: FORMULATION COMBINÉE DE TROIS COMPOSÉS ANTIVIRAUX (COMBINATION FORMULATION OF THREE ANTIVIRAL COMPOUNDS)
Estimated Expiration: ⤷  Sign Up

Israel

Patent: 3155
Patent: פורמולציה משולבת של שלוש תרכובות אנטי-ויראליות (Combination formulation of three antiviral compounds)
Estimated Expiration: ⤷  Sign Up

Japan

Patent: 19517492
Patent: 3種の抗ウイルス化合物の組み合わせ製剤
Estimated Expiration: ⤷  Sign Up

Mexico

Patent: 18014790
Patent: FORMULACION COMBINADA DE TRES COMPUESTOS ANTIVIRALES. (COMBINATION FORMULATION OF THREE ANTIVIRAL COMPOUNDS.)
Estimated Expiration: ⤷  Sign Up

Morocco

Patent: 142
Patent: FORMULATION COMBINÉE DE TROIS COMPOSÉS ANTIVIRAUX
Estimated Expiration: ⤷  Sign Up

Singapore

Patent: 201810189S
Patent: COMBINATION FORMULATION OF THREE ANTIVIRAL COMPOUNDS
Estimated Expiration: ⤷  Sign Up

South Korea

Patent: 190014536
Patent: 3종의 항바이러스 화합물의 조합 제제
Estimated Expiration: ⤷  Sign Up

Taiwan

Patent: 1818932
Patent: Combination formulation of three antiviral compounds
Estimated Expiration: ⤷  Sign Up

Uruguay

Patent: 261
Patent: FORMULACIÓN COMBINADA DE TRES COMPUESTOS ANTIVIRALES
Estimated Expiration: ⤷  Sign Up

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

See the table below for additional patents covering VOSEVI around the world.

Country Patent Number Title Estimated Expiration
San Marino T201500285 (S)-ISOPROPIL 2-(((S)-(((2R,3R,4R,5R)-5-(2,4-DIOSSO-3,4-DIIDROPIRIMIDIN-1-(2H)-IL)-4-FLUORO-3-IDROSSI-4-METILTETRAIDROFURAN-2-IL)METOSSI)(FENOSSI)FOSFORIL)AMMINO)PROPANOATO CRISTALLINO ⤷  Sign Up
Eurasian Patent Organization 027296 КОМПОЗИЦИИ И СПОСОБЫ ЛЕЧЕНИЯ ВИРУСНОГО ГЕПАТИТА C (COMPOSITIONS AND METHODS FOR TREATING HEPATITIS C VIRUS) ⤷  Sign Up
Spain 2492470 ⤷  Sign Up
Eurasian Patent Organization 201591244 ПРОТИВОВИРУСНЫЕ СОЕДИНЕНИЯ ⤷  Sign Up
Morocco 45142 FORMULATION COMBINÉE DE TROIS COMPOSÉS ANTIVIRAUX ⤷  Sign Up
European Patent Office 2432792 PROCÉDÉ DE PRODUCTION D'ESTER DE N-[(2'R)-2'-DÉSOXY-2'-FLUORO-2'-MÉTHYL-P-PHÉNYL-5' -URIDYLYL]-L-ALANINE 1-MÉTHYLÉTHYLE (AND PROCESS FOR THE PREPARATION OF N-[(2'R)-2'-DEOXY-2'-FLUORO-2'-METHYL-P-PHENYL-5'-URIDYLYL]-L-ALANINE 1-METHYLETHYL ESTER) ⤷  Sign Up
Slovenia 3650014 ⤷  Sign Up
>Country >Patent Number >Title >Estimated Expiration

Supplementary Protection Certificates for VOSEVI

Patent Number Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
2203462 300704 Netherlands ⤷  Sign Up PRODUCT NAME: SOFOSBUVIR; REGISTRATION NO/DATE: EU/1/13/894/001-002 20140117
2203462 132014902310732 Italy ⤷  Sign Up PRODUCT NAME: SOFOSBUVIR(SOVALDI); AUTHORISATION NUMBER(S) AND DATE(S): EU/1/13/894, 20140117
2203462 C02203462/01 Switzerland ⤷  Sign Up PRODUCT NAME: SOFOSBUVIR; REGISTRATION NO/DATE: SWISSMEDIC 63218 18.03.2014
2203462 CR 2014 00061 Denmark ⤷  Sign Up PRODUCT NAME: SOFOSBUVIR; REG. NO/DATE: EU/1/13/894/001-002 20140117
2203462 214 5029-2014 Slovakia ⤷  Sign Up PRODUCT NAME: SOFOSBUVIR; REGISTRATION NO/DATE: EU/1/13/894 20140117
2203462 1490066-6 Sweden ⤷  Sign Up PRODUCT NAME: SOFOSBUVIR
2203462 C201430078 Spain ⤷  Sign Up PRODUCT NAME: SOFOSBUVIR; NATIONAL AUTHORISATION NUMBER: EU/1/13/894; DATE OF AUTHORISATION: 20140116; NUMBER OF FIRST AUTHORISATION IN EUROPEAN ECONOMIC AREA (EEA): EU/1/13/894; DATE OF FIRST AUTHORISATION IN EEA: 20140116
>Patent Number >Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.